Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amprion has developed and commercialized the first validated seed amplification assay for detecting misfolded alpha-synuclein in cerebrospinal fluid. The test demonstrates high sensitivity and specificity for diagnosing synucleinopathies such as Parkinson’s disease, Lewy body dementia, and Alzheimer's with neocortical Lewy body co-pathology. The technology has been validated in leading journals (The Lancet Neurology, Alzheimer's & Dementia) and confirmed by autopsy studies[6]. The platform supports early diagnosis, patient stratification for clinical trials, and drug development partnerships.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Amprion.